Key Highlights

• Six abstracts from clinical studies of three key drug candidates have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
• Three abstracts will be presented as rapid oral presentations, considered prestigious and indicative of significant findings.
• Three abstracts will be presented as poster presentations, further expanding the visibility of the company’s pipeline.
• The selected drug candidates are Olverembatinib (HQP1351), Lisaftoclax (APG-2575), and Alrizomadlin (APG-115).

Details of Rapid Oral Presentations

1. Olverembatinib (HQP1351) Combined with Blinatumomab
   • Patient Group: Lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL).
   • Abstract Number: 6513
   • Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
   • Date/Time: May 30, 2026, 1:15–2:45 p.m. US Central Time
   • First Author: Dr. Elias Jabbour, University of Texas MD Anderson Cancer Center
2. Updated Efficacy and Safety of Olverembatinib as Second-Line Therapy in CP-CML
   • Patient Group: Chronic-phase chronic myeloid leukemia (CP-CML)
   • Abstract Number: 6510
   • Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
   • Date/Time: May 30, 2026, 1:15–2:45 p.m. US Central Time
   • First Author: Dr. Weiming Li, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
3. Alrizomadlin (APG-115) Alone or with Lisaftoclax (APG-2575) for Pediatric RMS or STSs
   • Patient Group: Pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)
   • Abstract Number: 10012
   • Session: Pediatric Oncology II
   • Date/Time: May 30, 2026, 8:00–9:30 a.m. US Central Time
   • First Author: Dr. Yizhuo Zhang, Sun Yat-sen University Cancer Center

Details of Poster Presentations

1. Olverembatinib in SDH-deficient Tumors
   • Abstract Number: 11539
   • Session: Sarcoma
   • Date/Time: June 1, 2026, 1:30–4:30 p.m. US Central Time
   • First Author: Dr. Haibo Qiu, Sun Yat-sen University Cancer Center
2. Phase 3 POLARIS-2 Study of Olverembatinib in CP-CML
   • Abstract Number: TPS6608
   • Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
   • Date/Time: June 1, 2026, 9:00 a.m.–12:00 p.m. US Central Time
   • First Author: Dr. Elias Jabbour, University of Texas MD Anderson Cancer Center
3. Global Phase 3 GLORA Study of Lisaftoclax in CLL/SLL
   • Patient Group: Previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
   • Abstract Number: TPS7101
   • Session: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
   • Date/Time: June 1, 2026, 9:00 a.m.–12:00 p.m. US Central Time
   • First Author: Dr. Matthew Steven Davids, Dana-Farber Cancer Institute

Potential Impact for Shareholders

• Rapid oral presentations at ASCO are highly competitive and reserved for significant advances in cancer therapy. The inclusion of three presentations suggests that Ascentage Pharma’s candidates are showing promising clinical results, which could be price sensitive.
• If any of these studies demonstrate superior efficacy or safety, or if their pivotal trials show positive results, it could lead to regulatory approvals, improved market share, and increased revenues.
• Olverembatinib is already the first third-generation BCR-ABL inhibitor approved in China, and Lisaftoclax is the first China-developed Bcl-2 selective inhibitor. These successes position Ascentage Pharma as a leader in innovative cancer therapies.
• Ongoing and upcoming phase 3 trials (POLARIS-2 for Olverembatinib and GLORA for Lisaftoclax) represent potential catalysts. Positive data and regulatory progress from these trials could significantly impact the company’s valuation and investor sentiment.
• There is a cautionary statement regarding Alrizomadlin (APG-115), noting that it may not ultimately be developed or marketed successfully. Investors should be aware of the risks associated with early-stage drug development.
• The company’s participation at ASCO, the world’s most prominent oncology meeting, is likely to increase international visibility and partnerships.

Leadership and Governance

• Dr. Yang Dajun serves as Chairman and Executive Director.
• The Board includes a diverse mix of executive, non-executive, and independent non-executive directors, including international experts in oncology and biotechnology.
• Ascentage Pharma is incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange (Stock Code: 6855).

Conclusion

The selection of multiple high-profile clinical data presentations at the 2026 ASCO Annual Meeting is a strong sign of innovation and progress at Ascentage Pharma. The potential for regulatory breakthroughs in hematologic malignancies and pediatric cancers, coupled with ongoing phase 3 trials, makes this announcement highly relevant for investors. The outcome of these presentations and ongoing studies could materially affect the company’s share price and future prospects.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Clinical trial outcomes and regulatory approvals are subject to uncertainty and risk. Investors should conduct their own research and consult professional advisors before making investment decisions. The company has issued a cautionary statement regarding the development of Alrizomadlin (APG-115), which may not be successfully brought to market.

View ASCENTAGE-B Historical chart here